Flaxseed and blood pressure: the PAD trial behind the headline.
A six-month randomized study enrolled people with peripheral artery disease and measured blood pressure, not cardiovascular event prevention.

Illustrative food image, not a photograph of the study intervention.
Who actually entered the study?
The population is essential to interpreting the flaxseed result. Rodriguez-Leyva and colleagues studied 110 patients with peripheral artery disease, or PAD. Their 2013 report described a prospective, double-blind, placebo-controlled randomized trial lasting six months. Participants consumed a variety of study foods containing milled flaxseed or placebo. This was not a trial of an unrestricted healthy population, a flaxseed oil capsule, or an entire plant-based dietary pattern. Naming PAD is more informative than simply saying “people with high blood pressure,” because the enrolled population determines how directly the result speaks to other groups.
Rodriguez-Leyva D, Weighell W, Edel AL, LaVallee R, Dibrov E, Pinneker R, Maddaford TG, Ramjiawan B, Aliani M, Guzman R, Pierce GN.. Hypertension (Dallas, Tex. : 1979), 2013. PMID 24126178 · DOI
The actual blood-pressure comparison
The stated purpose was to examine systolic and diastolic blood pressure in PAD patients. At six months, systolic pressure was approximately 10 millimeters of mercury lower in the flaxseed group than in the placebo group, while diastolic pressure was approximately 7 millimeters of mercury lower. These figures are reported between-group differences at that time point. They should not be relabeled as the amount every participant’s pressure fell from their own starting value. Random assignment and a placebo comparison make this a different kind of evidence from a survey linking habitual flaxseed intake with health.
Rodriguez-Leyva D, Weighell W, Edel AL, LaVallee R, Dibrov E, Pinneker R, Maddaford TG, Ramjiawan B, Aliani M, Guzman R, Pierce GN.. Hypertension (Dallas, Tex. : 1979), 2013. PMID 24126178 · DOI
A subgroup is not the whole sample
The report also described participants whose starting systolic pressure was at least 140 millimeters of mercury. In that subgroup, flaxseed ingestion was associated with reported reductions of 15 millimeters of mercury systolic and 7 millimeters of mercury diastolic. The authors stated that the antihypertensive effect was achieved selectively in hypertensive patients. The larger systolic number therefore should not replace the overall between-group result in a headline. It answers a narrower question within the trial. Keeping the baseline subgroup and the overall comparison separate prevents a real result from becoming an exaggerated universal expectation.
Rodriguez-Leyva D, Weighell W, Edel AL, LaVallee R, Dibrov E, Pinneker R, Maddaford TG, Ramjiawan B, Aliani M, Guzman R, Pierce GN.. Hypertension (Dallas, Tex. : 1979), 2013. PMID 24126178 · DOI
What the trial does not establish
Blood levels of alpha-linolenic acid and enterolignans increased in the flaxseed group, and the authors reported correlations between circulating measures and blood pressure. Correlation with a circulating compound does not isolate that compound as the cause of the effect of the study foods. Body weight did not differ significantly between groups at any time, according to the abstract. These additional measurements do not convert the study into an outcomes trial. Its blood-pressure findings do not demonstrate fewer heart attacks, strokes or deaths, reversal of PAD, or an equivalent effect from a different flax product or a home recipe. Six months is the reported observation window for these findings. It supplies no direct estimate of how long the blood-pressure difference would persist after the study foods stopped, and it cannot establish that other patient populations would respond in the same way.
Rodriguez-Leyva D, Weighell W, Edel AL, LaVallee R, Dibrov E, Pinneker R, Maddaford TG, Ramjiawan B, Aliani M, Guzman R, Pierce GN.. Hypertension (Dallas, Tex. : 1979), 2013. PMID 24126178 · DOI